期刊
GYNECOLOGICAL ENDOCRINOLOGY
卷 27, 期 8, 页码 587-592出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/09513590.2010.507283
关键词
Polycystic ovary syndrome; hyperandrogenism; anti-Mullerian Hormone; oral contraceptives; metformin
Objective. To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Mullerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism. Design. Prospective randomised study. Setting. Division of Endocrinology and Human Reproduction, Aristotle University of Thessaloniki. Patients. Forty-five (45) women with PCOS diagnosed according to the criteria proposed in 1990 by the NIH. Interventions. Women with PCOS were randomised into three groups, all treated for 6 months: Group A received an OC containing 35 mg ethinylestradiol plus 2 mg cyproterone acetate, Group B received an OC containing 30 mg ethinylestradiol plus 3 mg drospirenone and Group C received metformin 850 mg x 2. Main outcome measure(s). Anti-Mullerian hormone levels were measured by a specific ELISA. Results. AMH was significantly decreased under treatment with 35 mu g ethinylestradiol plus 2 mg cyproterone acetate (p = 0.002 at 3 months and p < 0.001 at 6 months). Treatment with 30 mu g ethinylestradiol plus 3 mg drospirenone, and treatment with metformin 850 mg x 2 did not significantly affect serum AMH levels. AMH was significantly decreased under OCs treatment compared to metformin 850 mg x 2 (p = 0.005). Conclusion(s). AMH serum levels were significantly decreased under treatment with 35 mu g ethinylestradiol plus 2 mg cyproterone acetate, due to decrease in androgens and suppression of gonadotropins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据